Compare BioNano Genomics Inc (BNGO) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Fortinet Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Fortinet Inc trades at $161.63 (market cap $118.78B). The key difference: Fortinet Inc is far larger — about 8695.5× BioNano Genomics Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FTNT | |
|---|---|---|
Market Cap | $13.66M | $118.78B |
Sector | Health | Technology |
52-Week High | $4.92 | $168.29 |
52-Week Low | $1.06 | $75.23 |
Enterprise Value | $16.26M | $115.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Fortinet (FTNT) trades at $164.09, down slightly by 0.07% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with revenue growing from $6.0B in 2024 to $6.8B in 2025 and net income reaching $1.85B. Recent Q2 2026 earnings beat expectations with $0.90 EPS versus $0.746 expected, continuing a pattern of strong quarterly performance. Analyst consensus remains positive with a $174.50 price target representing 6% upside potential from current levels.
Fortinet presents a compelling growth story with cybersecurity demand accelerating amid AI adoption, though elevated valuation metrics (P/E 57.2, P/S 16.08) require continued execution. Key risks include competitive pressures in the cybersecurity space and the stock's premium pricing relative to historical norms. The combination of strong earnings momentum, institutional support, and positive industry trends supports a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
